Biotech Company Previews Key Data and Findings for ASH 2021

In preparation for presenting at the 2021 American Society of Hematology (ASH) Annual Meeting and Exposition, biotechnology company Amgen recently shared a preview of the data of a follow-up to a phase 3 trial focused on pediatric patients and the initial safety and efficacy results of the addition of KYPROLIS to the treatment for patients with relapsed/refractory acute lymphoblastic leukemia (ALL). Amgen has over 15 sponsored clinical studies and abstracts this year that will be included in the meeting.

Amgen highlighted its study and results of an updated phase 3 trial of over 200 children with high-risk first relapse B-cell precursor acute lymphoblastic leukemia (B-ALL). Data indicated that when including BLINCYTO® (blinatumomab) as part of Amgen’s bispecific T-cell engager (BiTE®) platform, there was an improvement to patients’ event-free survival and overall survival when compared to allogeneic hematopoietic stem cell transplant (alloHSCT).

Also noted in Amgen’s press release prior to ASH was the promising results of a study examining the combination of KYPROLIS with vincristine, dexamethasone, PEG-asparaginase, daunorubicin (VXLD) induction therapy in children with relapsed/refractory ALL. Using this combination of treatment, they found efficacy in pediatric patients experiencing highly advanced forms of the disease.

Amgen is also connected to an oral presentation during ASH about exposure to Nplate during pregnancy and the outcomes of the fetuses and infants. They shared in their preview that there were no safety concerns identified from the analyses of the Pregnancy Surveillance Program (PSP).

Dr. David M. Reese, Executive Vice President of Research and Development for Amgen, reiterated the company’s “commitment to reaching more patients with [their] innovative hematology medicines and improving the patient experience by exploring more convenient administrations for people living with blood cancers [1].”

Source:

[1] Amgen. (2021, December 7). Amgen announces new data being presented at ASH 2021[Press release]. https://www.obroncology.com/news/amgen-announces-new-data-being-presented-at-ash-2021

Most Recent

Psoriasis

Rheumatology

Assessing Topical Rosuvastatin and Melatonin in Psoriasis

A preliminary clinical trial suggests that topical rosuvastatin or melatonin are effective at controlling psoriatic skin rashes, with significant benefits reported on days 30 and 60. Psoriasis, a chronic inflammatory skin disorder affecting about 3% of the population, typically manifests in adolescence or later adulthood. The most common form is chronic plaque psoriasis, characterized by...

Psoriasis

Rheumatology

Tildrakizumab's Work Productivity Benefits for Psoriasis Patients

A new clinical study shows that tildrakizumab effectively improves the quality of life and enhances the work productivity of those living with psoriasis. Psoriasis is a prevalent chronic inflammatory disorder affecting about 3% of US individuals aged 20 and older, making it a significant immune-mediated disease in the US. The economic burden of psoriasis is...

Cardiovascular Risk Management

Psoriasis

Rheumatology

Targeting Cardiovascular Comorbidities in Psoriasis

An updated review highlights the role of dysregulated adipokines in cardiovascular comorbidities in psoriasis and finds that biologics exert a cardioprotective role in some cases. Psoriasis is a prevalent chronic, inflammatory, multi-organ, systemic disease affecting millions worldwide. Its most common form, plaque psoriasis, manifests as erythematous plaques with silvery scales, notably on the elbows, knees,...